

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

(1) PROPOSED ADOPTION OF THE 2026 H SHARE SCHEME; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The board of directors (the **“Board”**) of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the **“Company”**) hereby announces that the Board has resolved and approved, among others: (i) the proposed 2026 H share (**“H Share(s)”**) award and trust scheme (the **“2026 H Share Scheme”**); and (ii) the proposed amendments to the articles of association of the Company (the **“Articles of Association”**) (the **“Proposed Amendments”**).

1. PROPOSED ADOPTION OF THE 2026 H SHARE SCHEME

In order to ensure the continuity, compliance and operability of the Company's equity incentive mechanism, to fully mobilize the enthusiasm and creativity of employees, enhance the cohesion of the core team and the Company's core competitiveness, and to promote the Company's continuous, stable and high-quality development, the Board has resolved and approved to adopt the 2026 H Share Scheme for a limit of 28,000,000 H Shares, sourced from a combination of treasury H Shares that may be repurchased and new H Shares that may be issued by the Company. It is contemplated that the 2026 H Share Scheme will be valid for a period of 10 years from the date of its adoption. The provisions of the 2026 H Share Scheme will comply with the requirements of Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The proposed 2026 H Share Scheme shall become effective upon the passing of the resolution by the shareholders of the Company (the **“Shareholders”**) to approve the adoption of the 2026 H Share Scheme. In connection with the proposed adoption of the 2026 H Share Scheme, the Board will also propose for the Shareholders to grant a repurchase mandate to the Board for, amongst others, fulfilment of the 2026 H Share Scheme, and to authorize the Board and its delegates to administer the 2026 H Share Scheme.

2. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In order to comprehensively implement the latest requirements of applicable laws, regulations and normative documents, the Board has resolved to amend the Articles of Association in accordance with the Guidelines on Articles of Association of Listed Companies (2025 Revision), the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange (2026 Revision), and other applicable regulatory requirements.

The Proposed Amendments primarily include:

- 1) further standardizing the wording of provisions in the Articles of Association in accordance with the text of applicable regulatory requirements;
- 2) clarifying matters relating to guarantee arrangements, connected transactions and actual controllers; and
- 3) making corresponding amendments or deletions to provisions that are no longer applicable due to updates to relevant rules.

Save for the above, there are no material amendments to other provisions of the Articles of Association. Non-material amendments include adjustments to the numbering of provisions in the Articles of Association, cross-references to other provisions in the main text and the table of contents.

Save for the Proposed Amendments, other provisions of the Articles of Association shall remain unchanged. Prior to the Proposed Amendments being approved by way of special resolution at the general meeting, the existing Articles of Association shall remain valid.

The Proposed Amendments are prepared in Chinese language. In the event of any discrepancy between the English translation and the Chinese version, the Chinese version shall prevail.

The Board has resolved to propose a resolution at the next general meeting to authorize the Company's legal representative and their authorized persons to handle the approval and filing procedures with the relevant regulatory authorities involved in such amendment, and to make adjustments to the wording of such amendment to the Articles of Association in accordance with the comments of the regulatory authorities. The Proposed Amendments to the Articles of Association is ultimately subject to the results approved by relevant regulatory authorities.

GENERAL INFORMATION

A circular containing, among others, details about the proposed 2026 H Share Scheme and the Proposed Amendments to the Articles of Association, together with a notice of the general meeting, will be despatched to the Shareholders as soon as practicable.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
July 24, 2026

As at the date of this announcement, the Board of Directors comprises Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors; Mr. LI Shing Chung Gilbert as employee representative Director; Ms. WAN Xuan as non-executive Director; Ms. LI Lihua, Prof. TSANG King Fung and Ms. SHEN Rong as independent non-executive Directors.